中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共7条，第1-7条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors (vol 0, pg 1, 2022) 期刊论文
ACTA PHARMACOLOGICA SINICA, 2022
作者:  Cao, Guo-zhen;  Ma, Li-ying;  Zhang, Zong-hui;  Wang, Xiao-lin;  Hua, Jing-han;  Zhang, Jia-hui;  Lv, Yang;  Zhang, Shao-bo;  Ou, Jian;  Lin, Wen-chu
收藏  |  浏览/下载：38/0  |  提交时间：2022/12/23
Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors 期刊论文
ACTA PHARMACOLOGICA SINICA, 2022
作者:  Cao, Guo-Zhen;  Ma, Li-Ying;  Zhang, Zong-Hui;  Wang, Xiao-Lin;  Hua, Jing-Han;  Zhang, Jia-Hui;  Lv, Yang;  Zhang, Shao-Bo;  Ou, Jian;  Lin, Wen-Chu
收藏  |  浏览/下载：48/0  |  提交时间：2022/12/22
small-cell lung cancer  H3  3  PARP1  PARP inhibitor  darinaparsin  combination treatment  
CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers 期刊论文
ACTA PHARMACOLOGICA SINICA, 2022
作者:  Cao, Jiang-yan;  Qi, Shuang;  Wu, Hong;  Wang, Ao-li;  Liu, Qing-wang;  Li, Xi-xiang;  Wang, Bei-lei;  Ge, Juan;  Zou, Feng-ming;  Chen, Cheng;  Wang, Jun-jie;  Hu, Chen;  Liu, Jing;  Wang, Wen-chao;  Liu, Qing-song
收藏  |  浏览/下载：104/0  |  提交时间：2022/03/28
HER2  breast cancers  gastric cancers  irreversible inhibitor  drug resistance  
FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11 期刊论文
ACTA PHARMACOLOGICA SINICA, 2021
作者:  Yin, Yan-ping;  Ma, Li-ying;  Cao, Guo-zhen;  Hua, Jing-han;  Lv, Xiao-tong;  Lin, Wen-chu
收藏  |  浏览/下载：71/0  |  提交时间：2022/01/10
small cell lung cancer  topotecan  DNA damage response  FK228  SLFN11  methylation  epigenetic modulation  
Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer 期刊论文
ACTA PHARMACOLOGICA SINICA, 2020
作者:  Yin, Yan-ping;  Shi, Wen-hao;  Deng, Ke;  Liu, Xiao-li;  Li, Hong;  Lv, Xiao-tong;  Lui, Vivian Wai Yan;  Ding, Chen;  Hong, Bo;  Lin, Wen-chu
收藏  |  浏览/下载：61/0  |  提交时间：2020/12/28
small cell lung cancer  obatoclax  bortezomib  carfilzomib  MCL-1  apoptosis  FOXM1  proteomics analysis  
Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52 期刊论文
ACTA PHARMACOLOGICA SINICA, 2020
作者:  Wang, Wen-liang;  Jiang, Zong-ru;  Hu, Chen;  Chen, Cheng;  Hu, Zhen-quan;  Wang, Ao-li;  Wang, Li;  Liu, Jing;  Wang, Wen-chao;  Liu, Qing-song
收藏  |  浏览/下载：62/0  |  提交时间：2020/11/26
PGK1  NG52  kinase inhibitor  Warburg effect  glioma  
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway 期刊论文
ACTA PHARMACOLOGICA SINICA, 2020
作者:  Chen, Cheng;  Cheng, Chuan-dong;  Wu, Hong;  Wang, Zuo-wei;  Wang, Li;  Jiang, Zong-ru;  Wang, Ao-li;  Hu, Chen;  Dong, Yong-fei;  Niu, Wan-xiang;  Qi, Shuang;  Qi, Zi-ping;  Liu, Jing;  Wang, Wen-chao;  Niu, Chao-shi;  Liu, Qing-song
浏览  |  Adobe PDF(3476Kb)  |  收藏  |  浏览/下载：101/36  |  提交时间：2020/11/26
glioblastoma  osimertinib  temozolamide  MAPK-signaling pathway  MNK  eukaryotic translation initiation factor 4E